The Experts below are selected from a list of 41814 Experts worldwide ranked by ideXlab platform
Vincenzo Bronte - One of the best experts on this subject based on the ideXlab platform.
-
myeloid derived Suppressor Cell heterogeneity in human cancers
Annals of the New York Academy of Sciences, 2014Co-Authors: Samantha Solito, Ilaria Marigo, Susanna Mandruzzato, Laura Pinton, Vera Damuzzo, Vincenzo BronteAbstract:: The dynamic interplay between cancer and host immune system often affects the process of myelopoiesis. As a consequence, tumor-derived factors sustain the accumulation and functional differentiation of myeloid Cells, including myeloid-derived Suppressor Cells (MDSCs), which can interfere with T Cell-mediated responses. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important not only to determine the presence of all MDSC subsets in each cancer patient, but also which MDSC subsets have clinical relevance in each tumor environment. In this review, we describe the differences between MDSC populations expanded within different tumor contexts and evaluate the prognostic significance of MDSC expansion in peripheral blood and within tumor masses of neoplastic patients.
-
myeloid derived Suppressor Cell heterogeneity and subset definition
Current Opinion in Immunology, 2010Co-Authors: Elisa Peranzoni, Serena Zilio, Ilaria Marigo, Luigi Dolcetti, Paola Zanovello, Susanna Mandruzzato, Vincenzo BronteAbstract:Myeloid derived Suppressor Cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term ‘heterogeneous’ remains the first, informal feature commonly attributed to this population. It is clear that CD11b + Gr-1 + Cells are part of a myeloid macropopulation, which comprises at least two subsets of polymorphonuclear and monocytic Cells with different immunosuppressive properties. While recent literature shows substantial agreement on the immunoregulatory property of the monocytic MDSC subset, there is still contrasting evidence on the role of the granulocytic fraction. Moreover, this dichotomy holds true for human MDSCs. We attempt here to summarize conflicting findings in the field and provide some possible, unifying explanations.
-
il4rα myeloid derived Suppressor Cell expansion in cancer patients
Journal of Immunology, 2009Co-Authors: Susanna Mandruzzato, Samantha Solito, Erika Falisi, Samuela Francescato, Vanna Chiarionsileni, Simone Mocellin, Antonio Zanon, Carlo Riccardo Rossi, Donato Nitti, Vincenzo BronteAbstract:Myeloid-derived Suppressor Cells (MDSC) contribute to immune dysfunctions induced by tumors both in experimental models and patients. In mice, MDSC are phenotypically heterogeneous Cells that vary in their surface markers, likely depending on soluble factors produced by different tumors. We recently described a subset of inflammatory monocytes with immunosuppressive properties that can be found within the tumor mass, blood, and lymphoid organs of tumor-bearing mice. These Cells expressed the α-chain of the receptor for IL-4 (IL4Rα) that was critical for their negative activity on CD8 + T Cells. In cancer patients, the nature of MDSC is still poorly defined because evidence exists for both monocytic and granulocytic features. We show in this study that myeloid Cells with immunosuppressive properties accumulate both in mononuclear and polymorphonuclear fractions of circulating blood leukocytes of patients with colon cancer and melanoma, thus unveiling a generalized alteration in the homeostasis of the myeloid compartment. Similarly to mouse MDSC, IL4Rα is up-regulated in both myeloid populations but its presence correlates with an immunosuppressive phenotype only when mononuclear Cells, but not granulocytes, of tumor-bearing patients are considered.
Susanna Mandruzzato - One of the best experts on this subject based on the ideXlab platform.
-
myeloid derived Suppressor Cell heterogeneity in human cancers
Annals of the New York Academy of Sciences, 2014Co-Authors: Samantha Solito, Ilaria Marigo, Susanna Mandruzzato, Laura Pinton, Vera Damuzzo, Vincenzo BronteAbstract:: The dynamic interplay between cancer and host immune system often affects the process of myelopoiesis. As a consequence, tumor-derived factors sustain the accumulation and functional differentiation of myeloid Cells, including myeloid-derived Suppressor Cells (MDSCs), which can interfere with T Cell-mediated responses. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important not only to determine the presence of all MDSC subsets in each cancer patient, but also which MDSC subsets have clinical relevance in each tumor environment. In this review, we describe the differences between MDSC populations expanded within different tumor contexts and evaluate the prognostic significance of MDSC expansion in peripheral blood and within tumor masses of neoplastic patients.
-
myeloid derived Suppressor Cell heterogeneity and subset definition
Current Opinion in Immunology, 2010Co-Authors: Elisa Peranzoni, Serena Zilio, Ilaria Marigo, Luigi Dolcetti, Paola Zanovello, Susanna Mandruzzato, Vincenzo BronteAbstract:Myeloid derived Suppressor Cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term ‘heterogeneous’ remains the first, informal feature commonly attributed to this population. It is clear that CD11b + Gr-1 + Cells are part of a myeloid macropopulation, which comprises at least two subsets of polymorphonuclear and monocytic Cells with different immunosuppressive properties. While recent literature shows substantial agreement on the immunoregulatory property of the monocytic MDSC subset, there is still contrasting evidence on the role of the granulocytic fraction. Moreover, this dichotomy holds true for human MDSCs. We attempt here to summarize conflicting findings in the field and provide some possible, unifying explanations.
-
il4rα myeloid derived Suppressor Cell expansion in cancer patients
Journal of Immunology, 2009Co-Authors: Susanna Mandruzzato, Samantha Solito, Erika Falisi, Samuela Francescato, Vanna Chiarionsileni, Simone Mocellin, Antonio Zanon, Carlo Riccardo Rossi, Donato Nitti, Vincenzo BronteAbstract:Myeloid-derived Suppressor Cells (MDSC) contribute to immune dysfunctions induced by tumors both in experimental models and patients. In mice, MDSC are phenotypically heterogeneous Cells that vary in their surface markers, likely depending on soluble factors produced by different tumors. We recently described a subset of inflammatory monocytes with immunosuppressive properties that can be found within the tumor mass, blood, and lymphoid organs of tumor-bearing mice. These Cells expressed the α-chain of the receptor for IL-4 (IL4Rα) that was critical for their negative activity on CD8 + T Cells. In cancer patients, the nature of MDSC is still poorly defined because evidence exists for both monocytic and granulocytic features. We show in this study that myeloid Cells with immunosuppressive properties accumulate both in mononuclear and polymorphonuclear fractions of circulating blood leukocytes of patients with colon cancer and melanoma, thus unveiling a generalized alteration in the homeostasis of the myeloid compartment. Similarly to mouse MDSC, IL4Rα is up-regulated in both myeloid populations but its presence correlates with an immunosuppressive phenotype only when mononuclear Cells, but not granulocytes, of tumor-bearing patients are considered.
Niek N Sanders - One of the best experts on this subject based on the ideXlab platform.
-
In vitro exploration of a myeloid-derived Suppressor Cell line as vehicle for cancer gene therapy
Cancer Gene Therapy, 2016Co-Authors: Sofie Denies, Francis Combes, C Ghekiere, S. Mc Cafferty, Laetitia Cicchelero, Niek N SandersAbstract:In vitro exploration of a myeloid-derived Suppressor Cell line as vehicle for cancer gene therapy
James A. Hutchinson - One of the best experts on this subject based on the ideXlab platform.
-
Alternative approaches to myeloid Suppressor Cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs
Transplantation Research, 2012Co-Authors: Paloma Riquelme, Edward K. Geissler, James A. HutchinsonAbstract:Several types of myeloid Suppressor Cell are currently being developed as Cell-based immunosuppressive agents. Despite detailed knowledge about the molecular and Cellular functions of these Cell types, expert opinions differ on how to best implement such therapies in solid organ transplantation. Efforts in our laboratory to develop a Cell-based medicinal product for promoting tolerance in renal transplant patients have focused on a type of Suppressor macrophage, which we call the regulatory macrophage (M reg). Our favoured clinical strategy is to administer donor-derived M regs to recipients one week prior to transplantation. In contrast, many groups working with tolerogenic dendritic Cells (DCs) advocate post-transplant administration of recipient-derived Cells. A third alternative, using myeloid-derived Suppressor Cells, presumably demands that Cells are given around the time of transplantation, so that they can infiltrate the graft to create a suppressive environment. On present evidence, it is not possible to say which Cell type and treatment strategy might be clinically superior. This review seeks to position our basic scientific and early-stage clinical studies of human regulatory macrophages within the broader context of myeloid Suppressor Cell therapy in transplantation.
Ilaria Marigo - One of the best experts on this subject based on the ideXlab platform.
-
myeloid derived Suppressor Cell heterogeneity in human cancers
Annals of the New York Academy of Sciences, 2014Co-Authors: Samantha Solito, Ilaria Marigo, Susanna Mandruzzato, Laura Pinton, Vera Damuzzo, Vincenzo BronteAbstract:: The dynamic interplay between cancer and host immune system often affects the process of myelopoiesis. As a consequence, tumor-derived factors sustain the accumulation and functional differentiation of myeloid Cells, including myeloid-derived Suppressor Cells (MDSCs), which can interfere with T Cell-mediated responses. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important not only to determine the presence of all MDSC subsets in each cancer patient, but also which MDSC subsets have clinical relevance in each tumor environment. In this review, we describe the differences between MDSC populations expanded within different tumor contexts and evaluate the prognostic significance of MDSC expansion in peripheral blood and within tumor masses of neoplastic patients.
-
myeloid derived Suppressor Cell heterogeneity and subset definition
Current Opinion in Immunology, 2010Co-Authors: Elisa Peranzoni, Serena Zilio, Ilaria Marigo, Luigi Dolcetti, Paola Zanovello, Susanna Mandruzzato, Vincenzo BronteAbstract:Myeloid derived Suppressor Cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term ‘heterogeneous’ remains the first, informal feature commonly attributed to this population. It is clear that CD11b + Gr-1 + Cells are part of a myeloid macropopulation, which comprises at least two subsets of polymorphonuclear and monocytic Cells with different immunosuppressive properties. While recent literature shows substantial agreement on the immunoregulatory property of the monocytic MDSC subset, there is still contrasting evidence on the role of the granulocytic fraction. Moreover, this dichotomy holds true for human MDSCs. We attempt here to summarize conflicting findings in the field and provide some possible, unifying explanations.